Embolic Protection Devices Reduce the Risk of New Lesions During TAVR

Embolic Protection DevicesThe aim of this study was to investigate the efficacy and safety of cerebral protection devices during transcatheter aortic valve replacement (TAVR).

 

All randomized controlled trials investigating the efficacy of cerebral protection devices during TAVR are relatively small and lack statistical power for definitive conclusions.

 

That is the reason why this systematic review and meta-analysis was carried out. All trials using any type of cerebral protection device during TAVR were analyzed and included.

 

Primary imaging efficacy endpoints were total lesion volume and number of new ischemic lesions per magnetic resonance imaging scan. The primary clinical efficacy endpoint was any deterioration in the National Institutes of Health Stroke Scale (NIHSS) score at hospital discharge.

 

Four randomized trials with 252 total patients were included; in them, the use of cerebral protection devices reduced the total volume of new cerebral lesions (p = 0.002) as well as the number of new lesions (p = 0.03).

 

Cerebral protection device use was associated with a trend toward lower risk for deterioration in the NIHSS score at discharge (risk ratio [RR]: 0.55; 95% confidence interval [CI]: 0.27 to 1.09; p = 0.09).

 

The risk for stroke and all-cause mortality was lower in the cerebral protection group, although the difference was not significant.

 

Conclusion

The use of cerebral protection devices during transcatheter aortic valve replacement was associated with less amount and lower volume of new cerebral lesions.

 

Original title: Neurological Outcomes with Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Reference: Gennaro Giustino et al. J Am Coll Cardiol Intv. 2016;9(20):2124-2133.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....